EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
暂无分享,去创建一个
W. Dixon | R. Landewé | L. Carmona | J. Askling | T. Kvien | U. Tarp | J. Listing | A. Zink | A. Finckh | M. Hetland | P. Nicola
[1] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[2] A. Silman,et al. European biologicals registers: methodology, selected results and perspectives , 2008, Annals of the rheumatic diseases.
[3] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Annals of Internal Medicine [serial online].
[4] J. Gómez-Reino,et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. , 2007, Arthritis and rheumatism.
[5] Terry M Therneau,et al. Primer: demystifying risk—understanding and communicating medical risks , 2007, Nature Clinical Practice Rheumatology.
[6] L. Jacobsson,et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists , 2007, Annals of the rheumatic diseases.
[7] Matthias Schneider,et al. Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.
[8] M. Sillanpää,et al. Replication in genetic studies of complex traits , 2004, Annals of human genetics.
[9] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[10] S. Schneeweiss,et al. Causation of Bias: The Episcope , 2001, Epidemiology.
[11] B. Jönsson,et al. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies , 2007, The European Journal of Health Economics.
[12] A. Silman,et al. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .